{"preliminary_commentary":{"by_channel":{"x_thread":16,"youtube":6,"podcast":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05024266\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["tislelizumab","albumin paclitaxel","carboplatin"]],"indication":"stage IIIA-IIIB (N2) lung squamous cell carcinoma","name":"TACT","nct_id":"NCT05024266","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tact-nct05024266. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TACT","arms":[{"description":"Tislelizumab 200mg d1, Albumin Paclitaxel 260mg/m2 d1, Carboplatin AUC5 d1, Q3W","label":"Tislelizumab + Albumin Paclitaxel + Carboplatin","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-08-31","type":"ESTIMATED"},"conditions":["Lung Squamous Cell Carcinoma","Neoadjuvant Therapy","Immunotherapy"],"enrollment":{"count":30,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Tislelizumab","otherNames":["Albumin Paclitaxel","Carboplatin"],"type":"DRUG"}],"last_update":"2021-08-27","lead_sponsor":"First Affiliated Hospital of Zhejiang University","official_title":"Tislelizumab Combined With Albumin Paclitaxel + Carboplatin as Neoadjuvant Therapy for Patients With Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma: A Single-arm, Single-center, Exploratory Phase II Clinical Study","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2022-08-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Major Pathological Response (MPR)","timeFrame":"2-4 weeks after resection"},{"measure":"Incidence of Treatment-Emergent Adverse Events","timeFrame":"Through the trial"}],"references":[{"citation":"Shan J, Liu Z, Chen S, Du C, Li B, Ruan L, Kong M, Wang L, Du M, Shi S, Qiao G, Tian T, Tu Z. Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy. BMC Med. 2024 Jun 10;22(1):234. doi: 10.1186/s12916-024-03462-4.","pmid":"38853265","type":"DERIVED"}],"start_date":{"date":"2021-08-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT05024266"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tact-nct05024266"}